Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment
Cancer Research and Treatment. 2023;55(2):468-478 
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer
The Oncologist. 2020;25(10):867-877
The challenges and benefits of toxicity management for tyrosine kinase inhibitor therapies in renal cancer
International Journal of Urological Nursing. 2021;15(3):144-144
Afatinib/gefitinib
Reactions Weekly. 2017;1679(1):16-16
Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib
Annals of Oncology. 2007;18(9):1582-1583
Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia
Journal of Blood Medicine. 2013;111
86. Herbimycin A, an inhibitor of tyrosine kinase prolongs survival of mice inoculated with myeloid leukemia C1 cells with high expression of v-abl tyrosine kinase
Biomedicine & Pharmacotherapy. 1992;46(5-7):281
Survival analysis of patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitor (TKI) treatment: A multi-center retrospective study
Thoracic Cancer. 2017;9(2):278-283
Goals of CML Treatment in the Tyrosine Kinase Inhibitor Era
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. 2016;53-67
Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression
The Oncologist. 2013;18(11):1192-1199